ArticleNature biomedical engineering2023
Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses.
Article in Nature biomedical engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Bacteria-mimicking cancer cells reprogram macrophages via multiple pattern recognition receptor pathways for cancer immunotherapy.Signal transduction and targeted therapy · 2026Article
- Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.Signal transduction and targeted therapy · 2026Review
- Engineering Oncolytic Virus-Armed Macrophages for Enhanced Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Macrophage Extracellular Traps in Immunity and Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Engineering macrophages for cancer immunotherapy: emerging insights and therapeutic potential.npj biomedical innovations · 2026Review
- Beyond conceptual advances in cancer therapies.Nature biomedical engineering · 2026Article
- Mechanobiological research fueling the advancement of mechanotherapy and mechanohealth.Mechanobiology in medicine · 2026Article
- Dendritic cell-liposome conjugates reverse immunosuppressive tumor microenvironment for inhibiting colitis-associated colorectal cancer.Acta pharmacologica Sinica · 2026Article
- Innate Immune-Cloaked Microgel-Coated Mesenchymal Stromal Cells Reverse Persistent Pulmonary Fibrosis via Reparative Macrophages.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Cancer Immunotherapy via Disruption of Integrin αvβ3 and CD47 Costabilization on Cancer Cell Surface.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Target cell adhesion limits macrophage phagocytosis and promotes trogocytosis.The Journal of cell biology · 2025Article
- Macrophages: sentinels, warriors, and healers.Human molecular genetics · 2025Review
- Spatial omics technology potentially promotes the progress of tumor immunotherapy.British journal of cancer · 2025Review
- Clustered macrophages cooperate to eliminate tumors via coordinated intrudopodia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Macrophage hitchhiking nanomedicine for enhanced β-elemene delivery and tumor therapy.Science advances · 2025Article
- Recent Insights into the Roles of PEST-Containing Nuclear Protein.Molecular biotechnology · 2025Review
- Potential of CLSPN as a therapeutic target in melanoma: a key player in melanoma progression and tumor microenvironment.Journal of translational medicine · 2025Article
- Syndecan-3 positively regulates the pro-inflammatory function of macrophages.Cellular and molecular life sciences : CMLS · 2025Article
- CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.Nature medicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
In solid tumours, the abundance of macrophages is typically associated with a poor prognosis. However, macrophage clusters in tumour-cell nests have been associated with survival in some tumour types. Here, by using tumour organoids comprising macrophages and cancer cells opsonized via a monoclonal antibody, we show that highly ordered clusters of macrophages cooperatively phagocytose cancer cells to suppress tumour growth. In mice with poorly immunogenic tumours, the systemic delivery of macrophages with signal-regulatory protein alpha (SIRPα) genetically knocked out or else with blockade of the CD47-SIRPα macrophage checkpoint was combined with the monoclonal antibody and subsequently triggered the production of endogenous tumour-opsonizing immunoglobulin G, substantially increased the survival of the animals and helped confer durable protection from tumour re-challenge and metastasis. Maximizing phagocytic potency by increasing macrophage numbers, by tumour-cell opsonization and by disrupting the phagocytic checkpoint CD47-SIRPα may lead to durable anti-tumour responses in solid cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.